| Hemoglobin, body mass index, and age as risk factors for paclitaxel-and oxaliplatin-induced peripheral neuropathy D Mizrahi, SB Park, T Li, HC Timmins, T Trinh, K Au, E Battaglini, D Wyld, ... JAMA network open 4 (2), e2036695-e2036695, 2021 | 86 | 2021 |
| Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy JM McCrary, D Goldstein, CX Sandler, BK Barry, M Marthick, HC Timmins, ... Supportive Care in Cancer 27, 3849-3857, 2019 | 77 | 2019 |
| Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials T Li, HC Timmins, T King, MC Kiernan, D Goldstein, SB Park Hematological oncology 38 (3), 229-243, 2020 | 48 | 2020 |
| Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review HC Timmins, D Mizrahi, T Li, MC Kiernan, D Goldstein, SB Park Journal of Cancer Survivorship, 1-15, 2021 | 41 | 2021 |
| Chemotherapy and peripheral neuropathy T Li, D Mizrahi, D Goldstein, MC Kiernan, SB Park Neurological Sciences 42 (10), 4109-4121, 2021 | 40 | 2021 |
| Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments JM McCrary, D Goldstein, T Trinh, HC Timmins, T Li, J Menant, ... Journal of the National Comprehensive Cancer Network 17 (8), 949-955, 2019 | 40 | 2019 |
| Quantification of small fiber neuropathy in chemotherapy-treated patients HC Timmins, T Li, MC Kiernan, LG Horvath, D Goldstein, SB Park The Journal of Pain 21 (1-2), 44-58, 2020 | 38 | 2020 |
| Optimizing clinical screening for chemotherapy-induced peripheral neuropathy JM McCrary, D Goldstein, T Trinh, HC Timmins, T Li, M Friedlander, ... Journal of Pain and Symptom Management 58 (6), 1023-1032, 2019 | 37 | 2019 |
| Comparison of cross‐sectional areas and distal‐proximal nerve ratios in amyotrophic lateral sclerosis YI Noto, N Garg, T Li, HC Timmins, SB Park, K Shibuya, N Shahrizaila, ... Muscle & Nerve 58 (6), 777-783, 2018 | 35 | 2018 |
| Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use T Li, SB Park, E Battaglini, MT King, MC Kiernan, D Goldstein, ... Quality of Life Research 31 (11), 3091-3107, 2022 | 34 | 2022 |
| Taxane-induced peripheral neuropathy: differences in patient report and objective assessment HC Timmins, T Li, MC Kiernan, S Baron-Hay, G Marx, F Boyle, ... Supportive Care in Cancer 28, 4459-4466, 2020 | 31 | 2020 |
| Peripheral neuropathy in hematologic malignancies–Past, present and future T Li, HC Timmins, HM Lazarus, SB Park Blood Reviews 43, 100653, 2020 | 29 | 2020 |
| Weekly paclitaxel‐induced neurotoxicity in breast cancer: outcomes and dose response HC Timmins, T Li, T Trinh, MC Kiernan, M Harrison, F Boyle, ... The Oncologist 26 (5), 366-374, 2021 | 26 | 2021 |
| The impact of obesity on neuropathy outcomes for paclitaxel-and oxaliplatin-treated cancer survivors HC Timmins, T Li, D Goldstein, T Trinh, D Mizrahi, M Harrison, LG Horvath, ... Journal of Cancer Survivorship, 1-10, 2021 | 20 | 2021 |
| Electrophysiological and phenotypic profiles of taxane-induced neuropathy HC Timmins, T Li, W Huynh, MC Kiernan, S Baron-Hay, F Boyle, ... Clinical Neurophysiology 131 (8), 1979-1985, 2020 | 20 | 2020 |
| Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes T Li, HC Timmins, T Trinh, D Mizrahi, M Harrison, LG Horvath, P Grimison, ... Journal of the National Comprehensive Cancer Network 21 (2), 125-132. e3, 2023 | 11 | 2023 |
| Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia SB Park, T Li, MC Kiernan, N Garg, I Wilson, R White, M Boggild, ... Muscle & nerve 66 (5), 576-582, 2022 | 6 | 2022 |
| Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes T Li, T Trinh, A Bosco, MC Kiernan, D Goldstein, SB Park Supportive Care in Cancer 32 (5), 1-11, 2024 | 5 | 2024 |
| Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes FM Mahfouz, T Li, M Joda, M Harrison, LG Horvath, P Grimison, T King, ... Supportive Care in Cancer 32 (1), 46, 2024 | 5 | 2024 |
| Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia T Li, T Kandula, RJ Cohn, MC Kiernan, SB Park, MA Farrar Clinical Neurophysiology 154, 157-168, 2023 | 5 | 2023 |
